Screening for B cell clone prior to taking a JAK2 inhibitor suggested
June 15, 2018
Patients with a pre-existing B-cell clone in their bone marrow are more likely to develop lymphoma after taking a JAK2 inhibitor, a study from Austria has found. Heinz Gisslinger, MD, found that patients with this alteration in the B cell lineage, who had taken a JAK2 inhibitor, were 16 times more likely to develop B Cell Lymphoma compared to patients who did not have clonal B cells.â€‹
This is something to discuss with your physician to ensure that you are adequately screened for all risk factors associated with having an MPN and any medication you are taking.